A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.
Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.
Local Control With Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results From a Prospective Clinical Trial.
Author Correction: Clonal evolution during metastatic spread in high-risk neuroblastoma.
Rapid COJEC without myeloablative therapy for high-risk neuroblastoma.
Clinical Significance of TERT Promoter Mutations in Neuroblastoma.
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma.
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete Remission.
The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial.
Titles as indexed on PubMed.